Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev 1990; 11(2): 266-301
Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev 1997; 18(4): 502-19
Pepe GJ, Albrecht ED. Actions of placental and fetal adrenal steroid hormones in primate pregnancy. Endocr Rev 1995; 16(5):608-48
Sojo-Aranda I, Alonso-Uriarte R, Gonzalez-Diddi M, Cortes-Gallegos V: The biological expression of natural progesterone. J Steroid Biochem, 1988; 31: 219-222
Roberts CP, Murphy AA. Endocrinopathies associated with recurrent pregnancy loss. Semin Reprod Med 2000; 18(4):357-362
Kato K, Mostafa MH, Mann K et al. Human chorionic gonadotrophin exhibits normal biological activity in patients with recurrent pregnancy loss. Gynecol Endocrinol. 2002; 16(3): 179-86
Szekeres-Bartho J, Barakonyi A, Par G et al. Progesterone as an immunomodulatory molecule. Int Immunopharmacol 2001; 1(6): 1037-48
Gruber CJ, Huber JC. The role of dydrogesterone in recurrent (habitual) abortion. J Steroid Biochem Mol Biol 2005;
Raghuparthy R, Mutawa EA et al. Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent miscarriage. BJOG 2005; 112: 1096-1101
Vignali M, Centinaio G. Efficacy of the vaginal administration of natural progesterone in patients with recurrent spontaneous hormone caused abortion Minerva Ginecol 2000, 52: 367-74
Tognoni G, Ferrario L, Inzalaco M et al. Progestagens in threatened abortion. Lancet 1980; 2: 1242-1243
Gerhard I, Gwinner B, Eggert-Kruse W et al. Double-blind controlled trial of progesterone substitution in threatened abortion. Biol Res Pregnancy Perinatol 1987;8:26-34
Reijinders FJ, Thomas CM, Doesburg WH et al. Endocrine effects of 17 alpha-hydroxyprogesterone caproate during early pregnancy: a double-blind clinical trial. Br J Obstet Gynaecol 1988; 95:462-68
Oates-Whitehead RM, Haas DM, Carrier JA. Progestogen for preventing miscarriage. Cochrane Databas Syst Rev 2003;4:CD003511
Clifford K, Rai R, Watson H and Regan L. An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases. Hum Reprod 1994; 9: 1328-1332
Sagle M, Bishop K, Ridley N et al. Recurrent early miscarriage and polycystic ovaries. Br Med J 1988; 297: 1027-8
Franks,S. Polycystic ovary syndrome. N.Engl.J.Med 1995; 333: 853-861
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostig criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 2004; 19: 41-47.
Balen AH, Laven JS, Tan SL and Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definition. Human Reproduction 2003; Update, in press.
Christensen JT, Boldsoen J and Westergaard JG. Ovarian volume in gynecologically healthy women using contraception or using IUD. Acta Obstet Gynecol Scand 1997; 76: 784-789.
Ehrmann DA, Barnes RB, Rosenfield /RL, Cavaghan MK and Imperial J. Prevalence of impaired, glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22: 141-146.
Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85: 2434-2438.
Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078-3082.
Balen AH, Tan SL, MacDougall J, Jacobs HS. Mescarriage rates following in vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Human Reproduction 1993; 8: 959-964.
Sagle M, Bishop K, Ridley N, Alexander FM, Michel M, Bonney RC, Beard RW, Franks S. Recurrent early miscarriage and polycystic ovaries. BMJ 1988; 297: 1027-1028.
Gray RH, Wu LY. Subfertility and risk of spontaneous abortion. Am J Public Health 2000; 90: 1452-1454.
Regan L, Braude PR, Trembath Pl. Influence of past reproductive performance on risk of spontaneous abortion. BMJ 1989; 299: 541-545.
Conway G. S., Jacobs H. S., Holly J. M. P. & Wass J. A. H. Effects of luteinizing hormone, insulin, insulin-like growth factor-1 and insulin-like growth factor small binding protein 1 in the polycystic ovary syndrome. Clin Endrocrinol 1990; 33: 593-603.
Regan L., Owen E. J. & Jacobs H.S. Hypersecretion of luteinizing hormone, infertility, and miscarriage. Lancet 1990; 336: 1141-1144.
Carmina E, Koyama T, Chang L, Stanczyk FZ, Lobo RA. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol 1992; 167: 1807-1812.
Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165-1174.
Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-bind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85: 139-146.
Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;1876-80.
Corrine R. Fantz, Samuel Dagogo-Jack, Jack H. Ladenson, Ann M. Gronowski, Thyroid function during pregnancy. Clinical Chemistry 1999; 45 (12): 2250-2258
John H. Lazarus, Amal Kokandi, Thyroid disease in relation to pregnancy: a decade of change. Clinical Endocrinology 2000; 53: 265-278
Kris Poppe1 and Daniel Glinoer, Thyroid autoimmunity and hypothyroidism before and during pregnancy. Human Reproduction Update 2003; 9 (2): 149±161
Zohar Nachum, Yardena Rakover, Ehud weiner, Eliezer Shalev. Grave’s disease in pregnancy: prospective evaluation of a selective invasive treatment protocol. American Journal of Obstetrics and Gynecology 2003; 189: 159-165
Esplin MS., Branch D. W., Silver R., Stagnaro-Green A. Thyroid autoantibodies is not associated with recurrent pregnancy loss. American Journal of Obstetrics and Gynaecology 1998; 179: 1583-1586
Federico Mecacci, Elena Parretti, Riccardo Cioni, Roberto Lucchetti, Alessandra Magrini, Pasquale La Torre, Marcella Mignosa, Luisa Acanfora, Giorgio Mello. Thyroid autoimmunity and its association with non-organ-specific antibodies and subclinical alterations of thyroid function in women with a history of pregnancy loss or preeclampsia. Journal of Reproductive Immunology 2000; 46: 39–50
William H. Kutteh M.D., Ph.D., Deborah L. Yetman, B.S., Alexander C. Carr, B.S., Leslie A. Beck, B.S., Richard T. Scott, Jr., M.D. Increased prevalence of antithyroid antibodies identified in women with recurrent pregnancy loss but not in women undergoing assisted reproduction. Fertility Sterility 1999; 71: 843– 8.
Lino Sieiro Netto, Claudia Medina Coeli, Eduardo Micmacher, Sheila Mamede Da Costa, Luiz Nazar, Daut GalvΌo, Alexandru Buescu, Mario Vaisman. Influence of Thyroid Autoimmunity and Maternal Age on the Risk of Miscarriage. American Journal of Reproductive Immunology 2004; 52: 312-316
F. H. Rushworth, M. Backos, R. Rai, I.T. Chilcot, N. Baxter, L. Regan. Prospective pregnancy outcome in untreated recurrent miscarriers with thyroid autoantibodies. Human Reproduction 2000; 15(7): 1637-1639
A. F. Muller, M.D., A. Verhoeff, M.D., M. J Mantel, M. Sc., Berghout, M.D A. Thyroid autoimmunity and abortion: a prospective study in women undergoing in vitro fertilization. Fertility and Sterility 1999; 71 (1): 30-34
Rhoda Wilson, Ph.D., Huang Ling, Ph.D., Marjorie A. MacLean, M.D.John Mooney, Ph.D., Denis Kinnane, M.D., James H. McKillop, M.D., James J. Walker, M.D. Thyroid antibody titer and avidity in patients with recurrent miscarriage. Fertility and Sterility 1999; 71 (3): 558-561
Alex Stagnaro-Green, MD, Daniel Glinoer, MD, PhD, Thyroid autoimmunity and the risk of miscarriage. Best Practice & Research Clinical Endocrinology & Metabolism 2004; 18 (2): 167–181
Dendrinos S., Papasteriades C., Tarassi K., Chrisodoulakos G., Prasinos G., Cretsas G. Thyroid autoimmunity in patients with recurrent spontaneous miscarriages. Gynecological Endocrinology 2000; 14 (4): 270-274
Stefanie S. Bussen, Thomas Steck. Thyroid Antibodies and their relation to antithrombin antibodies, anticardiolipin antibodies and lupus anticoagulant in women with recurrent spontaneous abortions (antithyroid, anticardiolipin and antithrombin autoantibodies and Lupus anticoagulant in habitual aborters). European Journal of Obstetrics & Gynecology and Reproductive Biology 1997; 74: 139-143
Lack of expression of endometrial prolactin in early implantation failure: a pilot study (Human Reproduction vol19 2004)
Regulated expression of STATs and its enhancement of PRL expression in Human Endometrial Stromal Cells in vitro(The Journal of Clinical and Metabolism 2002 by the Endocrine Society)
Endocrine abnormalities during the follicular phase in women with recurrent spontaneous abortion (Human Reproduction vol.14 1999)
Endocrinological and endometrial factors in recurrent miscarriage (British Journal of Obstetrics and Gynaecology Dec 2000 vol.107
Hyperprolactinemic recurrent miscarriage and results of randomized bromocriptine treatment trials (Fertility and Sterility vol.70 August 1998)
Current management of prolactinoma (Journal of Neuro-Oncology, 2001)
Pituitary tumors and pregnancy (Growth Hormone and IGF Research 13 (2003)
Κρεατσάς Γ. Σύγχρονη Γυναικολογία και Μαιευτική. Ιατρικές Εκδόσεις Πασχαλίδη, Αθήνα 1998
Μιχαλάς Σ. Επίτομη Μαιευτική και Γυναικολογία. Ιατρικές Εκδόσεις Παρισιάνου, Αθήνα 2000
Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Tracy T, Moore SK. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovarian syndrome. Metabolism 1999;48:1589–95.
Glueck CJ, Phillips H, Cameron D, Siere-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovarian syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001;75:46–52.
Rai R, Backos M, Rushworth F, Regan L. Polycystic ovaries and recurrent miscarriage—a reappraisal. Hum Reprod 2000;15:612–5.
Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovarian syndrome. J Clin Endocol Metab 1998;83:2694–8.
Hanson RL, Pratley RE, Bogardus C, Narayan KIMV, Roumain JML, Imperatore G, et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 2000;151:190–8.
Kutteh WH, Carney JL. Etiologic factors in women with a history of recurrent pregnancy loss. Obstet Gynecol 1999;93:42S.
Stephenson MD. Frequency of factors associated with habitual abortion in 197 couples. Fertil Steril 1996;66:241–91.
Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876–80.
Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovarian syndrome. J Clin Encocrinol Metab 1996;81:3299–306.
Gris JC, Ripart-Neeu S, Maugard C, Tailland ML, Brun S, Courtieu C, et al. Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study. Thromb Haemost 1997;77:1096–103.
Gris JC, Neveu S, Mares P, Biron C, Heton B, Schved JF. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology. J Lab Clin Med 1993; 122:606–15.
Velazquez EM, Mendoza S, Harner T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647–54.
Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450C17- activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335:617–23.